







ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa	University of Oxford	Emergent	IAVI		
MERS		IDT, Barinthus/University of Oxford			
Nipah		PHV, University of Oxford			
Rift Valley fever	UC Davis, Afrigen	Wageningen U., University of Oxford and KEMRI – Wellcome Trust			
Chikungunya				IVI/Bharat	Valneva
COVID-19 (*)		Gritstone			SK Bioscience, Biological E, Moderna, Clover, Novavax, AZ/Oxford, University of Hong Kong
Broadly protective Betacoronavirus (BPBC)	MigVax, VIDO, IVI, CPI/CalTech, Bharat/U Syd/ExcellGene, NEC, SK Bioscience, Intravacc, Panacea/THSTI, Gritstone	VBI			

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

		Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Disease X		Akagera	Tiba bio	BioNTech		
		Chungbuk University	Genova	Lemonex		
		University of Queensland	Celestial			
		Moderna	Emervax			
		SK bio	HMRI			
		University of Oxford	Imperial			
		Curevac	Amplitude			
		Boost Biopharma	Nagasaki University			



All .

DISEASE	DEVELOPER	PHASE	PLATFORM	CEPI FUNDING (IN USD)	
 Lassa	University of Oxford	Preclinical	Viral Vector	Up to \$19 million	(‡)
	IAVI	Phase 2	Viral Vector	Up to \$64.4 million	
	Emergent + PATH	Phase I	Viral vector	Up to \$36 million	
 MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million	(‡)
	IDT	Phase I	Viral vector	Up to \$36 million	
 Nipah	University of Oxford	Phase I	Viral Vector	Up to \$19 million	(‡)
	Auro Vaccines + PATH	Phase I	Protein based	Up to \$25 million	
	PHV	Phase I	Viral vector	Up to \$43.6 million	
 Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to \$40 million	
	Wageningen University	Phase I	Live attenuated	Up to \$38.4 million	
	University of Oxford and KEMRI-Wellcome Trust	Phase I	Viral Vector	Up to \$3.7 million	
	Afrigen	Preclinical	RNA	Up to \$6.2 million	
 Chikungunya	IVI/Bharat	Phase IIb/III	Inactivated	Up to \$14.1 million	
	Valneva	Registration	Live attenuated	Up to \$24.6 million	
 COVID-19	Gritstone	Phase I	RNA	Up to \$25.6 million	(**)
	SK Bioscience	Registration	Protein based	Up to \$210 million	
	Biological E	Registration	Protein based	Up to \$14 million	
	Moderna	Registration	Protein based	Up to \$1 million	
	Clover	Registration	Protein based	Up to \$397.4 million	
	AZ/University of Oxford	Registration	Viral vector	Up to \$384 million	
Novavax	Registration	Protein based	Up to \$399 million		

(‡) Includes Lassa, MERS and Nipah funding

(**) Includes COVID-19 variant and BPBC funding

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

 Broadly protective Beta-coronavirus (BPBC)	MigVax	Preclinical	Protein based	Up to \$4.3 million	
	BioNet	Preclinical	RNA	Up to \$16.9 million	
	VIDO	Preclinical	Protein based	Up to \$22 million	
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million	
	CPI/Caltech	Preclinical	Protein based	Up to \$30 million	
	NEC	Preclinical	RNA	Up to \$4.8 million	
	SK Bioscience	Preclinical	Protein based	Up to \$50 million	
	Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million	
	Intravacc	Preclinical	Protein based	Up to \$4.8 million	
	Gritstone	Phase I	RNA	Up to \$25.6 million	(**)
 Disease X	Akagera	Preclinical	RNA	Up to \$1.5 million	
	Amplitude	Preclinical	RNA	Up to \$1 million	
	BioNTech	Phase I	RNA	Up to \$90 million	
	Boost Biopharma	Preclinical	Protein based	Up to \$5 million	
	Celestial	Preclinical	RNA	Up to \$0.7 million	
	Chungbuk National University	Preclinical	RNA	Up to \$0.9 million	
	Curevac	Preclinical	RNA	Up to \$34 million	
	Emervax	Preclinical	RNA	Up to \$2.2 million	
	Gennova	Preclinical	RNA	Up to \$3.6 million	
	HMRI	Preclinical	RNA	Up to \$3.8 million	
	Imperial College London	Preclinical	RNA	Up to \$8.4 million	
	Lemonex	Phase I	RNA	Up to \$4.9 million	
	Moderna	Preclinical	RNA	Not yet at a stage where CEPI provides funding to Moderna.	
	Nagasaki University	Preclinical	RNA	Up to \$5 million	
	University of Oxford	Preclinical	Viral Vector	Up to \$80 million	
	University of Queensland	Preclinical	Protein based	Up to \$10.6 million	
SK Bioscience	Preclinical	RNA	Up to \$40 million		
Tiba bio	Preclinical	RNA	Up to \$2 million		